Bacterial antiviral defense suggests ancient link to human chromosome protection

A new antiviral defense system discovered by Columbia scientists could be adapted in the future into a gene editor that slows down aging in our cells and improves cancer therapies. The science-journalism coverage adds useful context, while the strongest evidential footing still comes from the underlying data, papers or institutional documentation.

This matters because biology becomes more informative when an observed effect begins to look like a mechanism rather than an isolated pattern. The gap between identifying a correlation in biological data and understanding the causal chain that produces it is routinely underestimated, and the history of biomedical research is populated with associations that collapsed when the mechanism was sought and not found. A result that comes with a proposed mechanism, even a partial one, is more useful than a purely descriptive finding because it generates testable predictions that can narrow the hypothesis space. Editors have highlighted the following attributes while ensuring the content's credibility: Add to Preferred Sources 1 DRT10 and Eco 3 DRT10 RTs. Https: //www. nature. com/articles/s41586-026-11250-8"> Secondary structure topology diagrams of Eco 1 DRT10 and Eco 3 DRT10 RTs.

Https: //www. nature. com/articles/s41586-026-11250-8 A new antiviral defense system discovered by Columbia scientists could be adapted in the future into a gene editor that slows. The newly discovered system, called DRT10 (for Defense-Associated Reverse Transcriptase 10), protects bacteria from viruses, like the CRISPR antiviral system discovered decades.

But unlike CRISPR, which works by cutting DNA, DRT10 employs a reverse transcriptase, an enzyme that gives it the power to manufacture DNA within the cell. One group of bacterial DNA-writing enzymes, aptly named the "Unknown Group" back in 2008, grabbed the lab's attention for its dozens of reverse transcriptases with still-unknown.

Because reverse transcription creates new DNA from strands of RNA, the enzymes are considered promising starting points for creating new gene-editing tools to write new. That was an irresistible biological mystery with the potential to yield entirely new biotechnology tools.

The broader interest lies in whether the reported effect points toward a real mechanism and not merely a reproducible but unexplained association. Biology has learned from decades of biomarker failures that correlation, even robust correlation, is not a substitute for mechanistic understanding. A pathway that can be traced from molecular interaction to cellular response to organismal phenotype provides a far stronger foundation for intervention than a statistical association discovered in a large dataset, however well the statistics are done.

Fernández leading the structural work that revealed how DRT10's protein and RNA components fit together. Discover the latest in science, tech, and space with over 100, 000 subscribers who rely on Phys. org for daily insights.

Because this item comes through Phys. org Biology as science journalism, it should be treated as contextual reporting rather than primary evidence. Good science reporting can identify why a result matters, connect it to the wider literature and make technical work readable, but the decisive evidence remains in the original paper, dataset, mission release or technical record. That distinction is especially important when a story is later repeated by aggregators, because repetition increases visibility, not evidential strength.

The next step is to test whether the effect repeats across different methods, cell types, model organisms and experimental conditions. Reproducibility is the first test, but mechanistic dissection is the second, and a result that passes both has a substantially better chance of translating into something clinically or biotechnologically useful. The path from a laboratory finding to an applied outcome typically takes a decade or more, and most findings do not complete it; the current result sits at the beginning of that process.

Source